Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Roivant Sciences (ROIV) over the last 5 years, with Sep 2025 value amounting to -19,492.87%.

  • Roivant Sciences' EBITDA Margin fell 1185683.00% to -19,492.87% in Q3 2025 from the same period last year, while for Sep 2025 it was -7,005.04%, marking a year-over-year decrease of 2111591.00%. This contributed to the annual value of -3,453.32% for FY2025, which is 1720025.00% down from last year.
  • Roivant Sciences' EBITDA Margin amounted to -19,492.87% in Q3 2025, which was down 48.46% from -13,130.05% recorded in Q2 2025.
  • Roivant Sciences' EBITDA Margin's 5-year high stood at 32,948.56% during Q4 2023, with a 5-year trough of -19,492.87% in Q3 2025.
  • Its 3-year average for EBITDA Margin is -2,346.76%, with a median of -4,452.92% in 2024.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 3,516,576bps in 2023, then plummeted by 3,599,115bps in 2024.
  • Over the past 5 years, Roivant Sciences' EBITDA Margin (Quarterly) stood at -1,010.73% in 2021, then plummeted by 120,647bps to -2,217.20% in 2022, then surged by 3,516,576bps to 32,948.56% in 2023, then plummeted by 3,599,115bps to -3,042.59% in 2024, then plummeted by 1,185,683bps to -19,492.87% in 2025.
  • Its EBITDA Margin stands at -19,492.87% for Q3 2025, versus -13,130.05% for Q2 2025 and -3,042.59% for Q4 2024.